Empowered Funds LLC Grows Stake in DENTSPLY SIRONA Inc. $XRAY

Key Points

• Empowered Funds LLC increased its DENTSPLY SIRONA stake by 515.3% in the first quarter, bringing its holdings to 126,601 shares valued at approximately $1.47 million. Institutional investors collectively own 95.7% of the company.
• DENTSPLY SIRONA’s latest quarterly results exceeded expectations, with EPS of $0.52 versus the $0.35 consensus and revenue of $898 million versus roughly $890 million expected. However, revenue fell 4.1% year over year, and 2026 revenue guidance was cautious.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $13.54. Several analysts recently cut their targets, while company directors purchased shares worth about $200,000 in June.

Empowered Funds LLC increased its holdings in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 515.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 126,601 shares of the medical instruments supplier's stock after acquiring an additional 106,024 shares during the quarter. Empowered Funds LLC owned approximately 0.06% of DENTSPLY SIRONA worth $1,469,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. First Eagle Investment Management LLC grew its position in shares of DENTSPLY SIRONA by 3.2% in the 4th quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier's stock worth $167,342,000 after buying an additional 458,744 shares during the last quarter. AQR Capital Management LLC boosted its holdings in DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier's stock worth $211,470,000 after acquiring an additional 6,970,086 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in DENTSPLY SIRONA by 0.9% in the third quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier's stock worth $129,445,000 after acquiring an additional 92,868 shares in the last quarter. Southpoint Capital Advisors LP purchased a new position in shares of DENTSPLY SIRONA in the 1st quarter valued at approximately $116,000,000. Finally, Armistice Capital LLC raised its holdings in shares of DENTSPLY SIRONA by 27.2% in the fourth quarter. Armistice Capital LLC now owns 7,298,000 shares of the medical instruments supplier's stock worth $83,416,000 after buying an additional 1,562,000 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors.

Insider Activity at DENTSPLY SIRONA

In other news, Director Brian P. Mckeon purchased 10,000 shares of the company's stock in a transaction dated Friday, June 12th. The stock was acquired at an average price of $10.12 per share, with a total value of $101,200.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at approximately $101,200. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Brian T. Gladden acquired 9,985 shares of the firm's stock in a transaction that occurred on Monday, June 15th. The stock was acquired at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the acquisition, the director directly owned 61,849 shares of the company's stock, valued at $619,726.98. The trade was a 19.25% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 35,160 shares of company stock valued at $351,179. 0.46% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Citigroup initiated coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They set a "sell" rating and a $10.00 price target on the stock. Weiss Ratings reissued a "sell (e+)" rating on shares of DENTSPLY SIRONA in a research report on Monday. Mizuho dropped their price objective on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a "neutral" rating on the stock in a report on Wednesday, May 6th. Barclays cut their price objective on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an "underweight" rating on the stock in a research note on Thursday, June 4th. Finally, UBS Group decreased their target price on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Thursday, May 7th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $13.54.

DENTSPLY SIRONA Stock Down 8.0%

Shares of NASDAQ XRAY opened at $12.12 on Friday. The firm has a market cap of $2.43 billion, a price-to-earnings ratio of -4.41, a price-to-earnings-growth ratio of 1.57 and a beta of 0.85. The company's 50-day simple moving average is $11.77 and its 200-day simple moving average is $11.89. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. DENTSPLY SIRONA Inc. has a 52-week low of $9.40 and a 52-week high of $14.86.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.17. The firm had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.74%. The company's revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts predict that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current fiscal year.

DENTSPLY SIRONA News Summary

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Adjusted earnings exceeded expectations: Q2 EPS was $0.52, above analyst estimates ranging from $0.35 to $0.36 and matching the year-ago result. Revenue of $898 million also surpassed the roughly $890 million consensus. Dentsply International Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Margins improved: Management highlighted better margins during the quarter, helping offset softer demand and supporting the earnings beat. The Wellspect business was a key sales-growth contributor. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales
• Neutral Sentiment: Full-year EPS guidance was maintained: DENTSPLY SIRONA reiterated 2026 adjusted EPS guidance of $1.40 to $1.50, which brackets the approximately $1.42 analyst consensus. DENTSPLY SIRONA Second-Quarter 2026 Results
• Negative Sentiment: Sales declined year over year: Q2 revenue fell 4.1%, as weakness in the company’s core dental business outweighed growth at Wellspect. This suggests that broader dental-market demand and utilization remain pressured. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales
• Negative Sentiment: Revenue guidance was cautious: The company forecast 2026 revenue of $3.5 billion to $3.6 billion, with the midpoint below the $3.6 billion consensus estimate. Investors appear to be prioritizing the weak organic-sales trend and outlook over the quarterly EPS beat.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source